We determined whether the high in vivo tumor transduction levels achieved by GALV-RRV has the potential to improve survival by evaluating prodrug activator gene therapy using GS4-CD and GS4-NTR in the intracerebral RG-2 glioma model. This evidence concerns the gene NTSR1 and glioma.